<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="100900">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01962259</url>
  </required_header>
  <id_info>
    <org_study_id>ACTIWE-1</org_study_id>
    <nct_id>NCT01962259</nct_id>
  </id_info>
  <brief_title>Active Commuting To Improve Well-being and Health in Everyday Life</brief_title>
  <acronym>GO-ACTIWE</acronym>
  <official_title>Active Commuting To Improve Well-being and Health in Everyday Life</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Copenhagen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Copenhagen University Hospital, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Copenhagen</source>
  <oversight_info>
    <authority>Denmark: Danish Dataprotection Agency</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of present randomized controlled trial is to evaluate the health effects of physical
      activity in transport and leisure time domains of everyday life and to develop durable
      physical activity regimens, i.e. to go from lifestyle intervention to daily lifestyle
      routine, in overweight individuals.

      Subjects will be randomized to 1 of 4 groups. 1: Vigorous intensity leisure time physical
      activity, 2: Moderate intensity leisure time activity, 3: Active commuting by bicycle, or 4:
      a non-intervention control group
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2013</start_date>
  <primary_completion_date type="Anticipated">October 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Peripheral insulin sensitivity (glucose clearance ml/min/kg fat-free mass/nM insulin)</measure>
    <time_frame>Change from baseline in peripheral insulin sensitivity at 3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measured using the hyper-insulinemic euglycaemic clamp</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Peripheral insulin sensitivity (glucose clearance ml/min/kg fat-free mass/nM insulin)</measure>
    <time_frame>Change from baseline in peripheral insulin sensitivity at 6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measured using the hyper-insulinemic euglycaemic clamp</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Haemostatic balance</measure>
    <time_frame>Change  from baseline in endogenous thrombin potential at 3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Blood coagulation measured by fasting levels of endogenous thrombin potential (nM x min)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Haemostatic balance</measure>
    <time_frame>Change from baseline in endogenous thrombin potential at 6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Blood coagulation measured by fasting levels of endogenous thrombin potential (nM x min)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glycaemic control</measure>
    <time_frame>Baseline, 3 and 6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Fasting plasma glucose, 1- and 2-hour plasma glucose and glucose area under the curve measured during an oral glucose tolerance test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Central insulin sensitivity</measure>
    <time_frame>Baseline, 3 and 6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Fasting plasma insulin, homeostasis model assessment insulin resistance and measures of central insulin sensitivity  derived from an oral glucose tolerance test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximal oxygen uptake (ml/O2/kg/min)</measure>
    <time_frame>Baseline, 3 and 6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measured using indirect calorimetry and an incremental bicycle protocol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Abdominal fat mass</measure>
    <time_frame>Baseline, 3 and 6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Visceral intrabdominal and subcutaneous fat mass determined by magnetic resonance imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolic syndrome</measure>
    <time_frame>Baseline, 3 and 6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>As measured by high density lipoprotein, triglycerides, waist circumference, blood pressure, mean arterial pressure, fasting glucose and composite metabolic syndrome scores</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Haemostatic balance II</measure>
    <time_frame>Baseline, 3 and 6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>1: Coagulation: Fibrinogen, Tissue factor(TF), prothrombin fragment 1+2. 2: Fibrinolysis: Tissue type plasminogen activator(tPA:AG), Plasminogen activator inhibitor type 1(PAI-1:AG). 3: Endothelial cell function: von Willebrand factor(vWF), Tissue factor pathway inhibitor (TFPI). 4: Inflammation: C-Reactive protein.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health related quality of life and other psycho-social outcomes</measure>
    <time_frame>Baseline, 3 and 6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measured using questionaries (SF-36), semi-structured interviews and observations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anthropometry</measure>
    <time_frame>Baseline, 3 and 6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measured using dual x-ray absorptiometry, height, weight, waist and hip circumference, sagittal abdominal height</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep habits</measure>
    <time_frame>Baseline, 3 and 6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Sleep duration and quality measured using accelerometers, logs and questionaires (Pittsburgh sleep quality index and Epworth sleepiness scale)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Skeletal muscle biopsy</measure>
    <time_frame>Baseline, 3 and 6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Biochemical, proteomics, metabolomics, genomics and morphological analyses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subcutaneous adipose tissue biopsy</measure>
    <time_frame>Baseline, 3 and 6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Biochemical, proteomics, metabolomics, genomics and morphological analyses</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Exercise compliance</measure>
    <time_frame>Baseline, 3 and 6 month</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Adherence to the exercise protocol as measured using heart rate and global positioning system monitors will be assessed and individually adjusted continuously over the course of the exercise intervention</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">175</enrollment>
  <condition>Overweight and Obesity</condition>
  <arm_group>
    <arm_group_label>Vigorous intensity LTPA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Leisure time physical activity (LTPA): Exercise intensity: 70% of maximal oxygen uptake (VO2 max); Energy expenditure: Females: 1600 kcal/week; Males: 2100 kcal/week</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Moderate intensity LTPA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Leisure time physical activity (LTPA): Exercise intensity: 50% VO2 max; Energy expenditure: Females: 1600 kcal/week; Males: 2100 kcal/week</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active commuting</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bicycling to/from work/school/university. No requirements for exercise intensity; Energy expenditure: Females: 1600 kcal/week; Males: 2100 kcal/week; Avg distance per day Females 9-15 km; Males 11-17 km</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Receives no intervention.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Physical activity</intervention_name>
    <arm_group_label>Vigorous intensity LTPA</arm_group_label>
    <arm_group_label>Moderate intensity LTPA</arm_group_label>
    <arm_group_label>Active commuting</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy

          -  No engagement in habitual structured physical activity

          -  Body mass index 25-35 kg/m2

          -  Body fat percentage &gt;32% for women and &gt;25% for men

          -  Maximum oxygen uptake (VO2max) &lt;40 ml O2/kg/min for women and &lt;45 ml O2/kg/min for
             men

          -  Ethnicity: Caucasian

        Exclusion Criteria:

          -  Chronic use of medicine

          -  Smoking

          -  Fasting plasma glucose &gt; 6,1 mmol/L

          -  Blood pressure &gt; 140/90 mm Hg

          -  Abnormal resting and working ECG

          -  Parents or siblings with diagnosed type 2 diabetes

          -  For women: Follicle stimulating hormone (FSH) concentration &gt; 35 milliunits/ml,
             pregnancy or planning of pregnancy within the coming year
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bente M Stallknecht, MD,PHD,DMSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Copenhagen, Department of Biomedical Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mads Rosenkilde, PhD</last_name>
    <phone>+45 26175847</phone>
    <email>madsrl@sund.ku.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bente M Stallknecht, MD</last_name>
    <phone>+45 35327540</phone>
    <email>bstall@sund.ku.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Copenhagen, Department of Biomedical Sciences</name>
      <address>
        <city>Copenhagen</city>
        <zip>2200</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mads Rosenkilde, PhD</last_name>
      <phone>+4526175847</phone>
      <email>madsrl@sund.ku.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <link>
    <url>http://go.ku.dk/actiwe</url>
    <description>Project homepage</description>
  </link>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 8, 2014</lastchanged_date>
  <firstreceived_date>September 25, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Copenhagen</investigator_affiliation>
    <investigator_full_name>Bente Merete Stallknecht</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
